Prem Watsa
Fairfax Financial Holdings
Prem Watsa Provention Bio Inc stake
total: 291
Fairfax Financial Holdings PRVB trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2023 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2023 Q2
According to 2026 Q2 report, Prem Watsa doesn't hold any Provention Bio Inc (PRVB) shares. To date, the estimated cost basis is nearly $24.09 for "buy" trades and estimated average "sell" price is $24.09. Fairfax Financial Holdings first purchased PRVB in 2023 Q1, initially acquiring 277,000 shares. Since the initial investment in Provention Bio Inc (PRVB), Fairfax Financial Holdings has made 1 more transaction.
When did Prem Watsa sell Provention Bio Inc (PRVB)?
Prem Watsa sold off the entire Provention Bio Inc (PRVB) position in 2023 Q2.
When did Prem Watsa buy Provention Bio Inc (PRVB)?
Prem Watsa first invested in Provention Bio Inc (PRVB) in 2023 Q1 at the reported quarter-end price of $24.09 per share.
What's the cost basis of Fairfax Financial Holdings's PRVB stake?
The estimated cost basis for Provention Bio Inc (PRVB) stake is around $24.09 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $24.09
- Weighted AVG sell price:
- $24.09
Prem Watsa's historical trades in Provention Bio Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$24.09
|
|
-100% (-277,000)
|
-0.38%
|
|
2023 Q1
|
0.38%
|
277,000
|
$24.09
|
$6,672,930
|
new
|
+0.38%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.